Compare DRD & ARQT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | DRD | ARQT |
|---|---|---|
| Founded | 1895 | 2016 |
| Country | South Africa | United States |
| Employees | 3410 | N/A |
| Industry | Precious Metals | Biotechnology: Pharmaceutical Preparations |
| Sector | Basic Materials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 3.4B | 3.3B |
| IPO Year | N/A | 2020 |
| Metric | DRD | ARQT |
|---|---|---|
| Price | $26.02 | $22.51 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 2 | 6 |
| Target Price | $32.63 | ★ $34.00 |
| AVG Volume (30 Days) | 310.5K | ★ 1.2M |
| Earning Date | 08-19-2026 | 05-05-2026 |
| Dividend Yield | ★ 2.23% | N/A |
| EPS Growth | N/A | ★ 88.79 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $376,072,000.00 |
| Revenue This Year | $34.35 | $34.46 |
| Revenue Next Year | $24.62 | $29.77 |
| P/E Ratio | $15.32 | ★ N/A |
| Revenue Growth | N/A | ★ 91.34 |
| 52 Week Low | $13.08 | $11.86 |
| 52 Week High | $39.37 | $31.77 |
| Indicator | DRD | ARQT |
|---|---|---|
| Relative Strength Index (RSI) | 27.93 | 37.45 |
| Support Level | $23.26 | $22.56 |
| Resistance Level | $30.91 | $27.26 |
| Average True Range (ATR) | 1.22 | 0.92 |
| MACD | -0.91 | -0.13 |
| Stochastic Oscillator | 3.35 | 22.56 |
DRDGold Ltd is a South African gold mining company engaged in surface gold tailings retreatment including exploration, extraction, processing, and smelting. Its reportable operating segments are; Ergo, FWGR, and Corporate office and other reconciling items. The Ergo is a surface gold retreatment operation that treats old slime dams and sand dumps to the south of Johannesburg's central business district as well as the East and Central Rand goldfields, and the FWGR which is a surface gold retreatment operation and treats old slime dams in the West Rand goldfields. The Ergo segment derives a vast majority of the company's revenue.
Arcutis Biotherapeutics Inc is a commercial-stage biopharmaceutical company focused on developing and commercializing treatments for dermatological diseases with high unmet medical needs. Its current portfolio is comprised of differentiated topical and systemic treatments with potential to treat immune-mediated dermatological diseases and conditions. The company's product candidate ZORYVE roflumilast cream, has completed pivotal Phase 3 clinical trials in plaque psoriasis, demonstrating symptomatic improvement and favorable tolerability in this population. The Company has one reportable segment relating to the development and commercialization of treatments for dermatological diseases.